After signing up to use GlaxoSmithKline’s adjuvant vaccine technology back in the summer, Canadian biotech Medicago has already finished off a phase1, and is now kicking on with several phase 2/3 trials.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,